Publications by authors named "Mark A Deeg"

Claim this Profile
A
Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Claire L Smith, Yan Jin, Eyas Raddad, Terry A McNearney, Xiao Ni, Mark A Deeg

Pharm Stat· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy.
Joanne Sloan-Lancaster, Eyas Raddad, Mark A Deeg, Michelle Eli, Amy Flynt

Clin Pharmacol Drug Dev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coding variants in and are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
Cristina B Guzman, Suman Duvvuru, Anthony Akkari, Pallav Bhatnagar, Chakib Battioui, Mark A Deeg

Hepatol Commun· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control.
Carlos I Alatorre, Byron J Hoogwerf, Mark A Deeg, David R Nelson, Theresa M Hunter

Curr Med Res Opin· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.
Stephen J Nicholls, Giacomo Ruotolo, H Bryan Brewer, Ming-Dauh Wang, Liping Liu, Mark A Deeg

J Clin Lipidol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus Insulin Glargine.
Liza L Ilag, Timothy M Costigan, Mark A Deeg, Robyn K Pollom, Curtis L Chang

Diabetes Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Mark A Deeg

Diabetes Care· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Chafiq Hamdouchi, Steven D Kahl, Anjana Patel Lewis, Guemalli R Cardona, Richard W Zink, Mark A Deeg

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Mark A Deeg

Diabetes Care· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive biomarkers of abdominal aortic aneurysm growth rate.
Mark A Deeg, C Arnoud Meijer, Lai Shan Chan, Lei Shen, Jan H N Lindeman

Curr Med Res Opin· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Mark A Deeg

Diabetes Care· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.
Christopher D Payne, Mark A Deeg, Melanie Chan, Lai Hock Tan, Elizabeth Smith LaBell

Br J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician preferences for extra-glycemic effects of type 2 diabetes treatments.
Christine Poulos, Juan Marcos González, Lauren J Lee, Kristin S Boye, F Reed Johnson, Mark A Deeg

Diabetes Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homocysteine levels and dementia risk in Yoruba and African Americans.
Hugh C Hendrie, Olusegun Baiyewu, Kathleen A Lane, Christianna Purnell, Sujuan Gao, Mark A Deeg

Int Psychogeriatr· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg

Cell Metab· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon.
John H Sloan, Robert W Siegel, Yvelina T Ivanova-Cox, David E Watson, Mark A Deeg

Clin Biochem· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic variation of GPLD1 associates with serum GPI-PLD levels: a preliminary study.
Mark A Deeg, Xiaoling Xuei, George Eckert, Robert V Considine, Ying Grace Li

Biochim Biophys Acta· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies.
Mark A Deeg, Meng H Tan

PPAR Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone.
Jason S Troutt, Robert W Siegel, Jinbiao Chen, John H Sloan, Mark A Deeg

Clin Chem· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance.
Nandita S Raikwar, Rosario F Bowen-Deeg, X Sean Du, Martin G Low, Mark A Deeg

Metabolism· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma glycosylphosphatidylinositol-specific phospholipase D predicts the change in insulin sensitivity in response to a low-fat but not a low-carbohydrate diet in obese women.
Dona L Gray, Kevin D O'Brien, David A D'Alessio, Bonnie J Brehm, Mark A Deeg

Metabolism· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of progressive aortic vasculopathy in a rat model of aging.
Steven J Miller, William C Watson, Kimberly A Kerr, Carlos A Labarrere, Neal X Chen, Mark A Deeg

Am J Physiol Heart Circ Physiol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Mark A Deeg, John B Buse, Ronald B Goldberg, David M Kendall, Anthony J Zagar

Diabetes Care· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D.
Mark A Deeg, Nandita S Raikwar, Cynthia Johnson, Craig D Williams

Transl Res· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary care physician treatment of low HDL: Rational approach or Pandora's Box?
Mark A Deeg, Sindhu Jacob, Jianzhao Shen, David G Marrero

J Clin Lipidol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis